Clinical Trial Update: A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/II trial evaluating mosunetuzumab in combination with CHOP or CHP-Polatuzumab Vedotin in B-cell non-Hodgkin lymphoma; the study has completed and resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Mosunetuzumab (BTCT4465A) (mosunetuzumab)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: B-cell Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-12-18